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1995; Krause et al., 2001). Gene-targeting experiments
have further obscured this issue; deletion of the CD34-
encoding gene in mice by two separate laboratories
has revealed only subtle phenotypes, with different and
opposing observations made for the independent
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strains (Cheng et al., 1996; Suzuki et al., 1996). TheCanada
discovery of two additional CD34-related genes (Podo-
calyxin and Endoglycan) with overlapping expression
patterns suggests that the minor phenotypes observedSummary
in CD34-deficient mice may reflect functional compen-
sationby these relatedmolecules (Doyonnas et al., 2001;CD34 is a cell-surface sialomucin expressed by hema-
Nielsen et al., 2002; Sassetti et al., 1998, 2000). Thus,topoietic stem cells (HSC), mast cells, and vascular
the use of mutant animals to delineate a function forendothelia. Despite its popularity as an HSC marker,
CD34 would require either the generation of compoundthe function of CD34 on hematopoietic cells remains
mutant mice lacking these related family members or aenigmatic. Here, we have addressed this issue by ex-
focused analysis of tissues that normally express CD34amining the behavior of mutant mast cells lacking
but not its homologs.CD34, the related sialomucin, CD43, or both mole-
In a recent survey of the expression pattern of CD34-cules. Loss of these molecules leads to a gene-dose-
related genes, we made an unexpected observation:dependent increase in mast cell homotypic aggrega-
CD34 but not Podocalyxin or Endoglycan is expressedtion with CD34/CD43KOs  CD43KO  CD34KO 
at high levels by murine mast cells (Drew et al., 2002).wild-type. Importantly, reexpression of CD34 or CD43
Despite their notoriety in the pathogenesis of diseasesin these cells caused reversal of this phenotype.
such as asthma, allergies, and autoimmune disease (Be-Furthermore, we find that loss of these sialomucins
noist and Mathis, 2002), mast cells are also importantprevents mast cell repopulation and hematopoietic
players in innate and adaptive immune responses (Galliprecursor reconstitution in vivo. Our data provide
and Nakae, 2003; Kawakami and Galli, 2002; Smith andclear-cut evidence for a hematopoietic function for
Weis, 1996). Murine mast cells can be broadly classifiedCD34 and suggest that it acts as a negative regulator
into two distinct groups based on their morphology,of cell adhesion.
granule protease content, and tissue localization: con-
nective tissue-type mast cells (CTMC) and mucosalIntroduction
mast cells (MMC) (Gurish and Boyce, 2002). CTMC re-
side predominantly in the skin and peritoneum and areCD34 is a highly glycosylated transmembrane protein
important sentinels in responding to bacterial infections,that is expressed by hematopoietic stem cells (HSC),
while MMC reside in the intestinal mucosa and play ahematopoietic progenitors, and vascular endothelia.
key role in responses to certain helminth infections (Gur-Since its discovery almost 20 years ago, it has become
ish et al., 2001). Mast cells are known to phagocytose,the most widely used marker for the enrichment of hu-
present antigen and secrete cytokines, and other inflam-man hematopoietic progenitors (reviewed in Gratama et
matory mediators (Mekori and Metcalfe, 2000). There-al., 2001; Krause et al., 1996). More recently, its use
fore, these cells are important in immune responses tofor the enrichment of the most primitive hematopoietic
a variety of pathogens.
progenitors/stem cells has come into question with the
Mast cells arise in the bone marrow from hematopoi-
discovery that both CD34 and CD34 cells have the
etic stem cells and are unusual in that they leave the
capacity to reconstitute all hematopoietic lineages in bonemarrowas immature precursors to enter peripheral
irradiated murine recipients (Bhatia et al., 1998; Ogawa, tissues, where they undergo terminal differentiation (Ka-
2002). Interestingly, CD34 expression by hematopoietic wakami and Galli, 2002). Little is known of the process
stem cells has been found to fluctuate as a function of that leads to their maturation, but, in vivo, it is critically
mammalian development and cell activation (Dao et al., dependent upon signaling through the stem cell factor
2003; Ogawa, 2002; Zanjani et al., 2003). Thus, it is likely receptor (SCF), c-kit (also known as SCF-R and mast
that the differences in the expression of CD34 by HSC cell growth factor receptor) (Galli, 2000). The develop-
reflect their activation or developmental status. ment and differentiation of a mast cell, including its
Given the widespread use of CD34 as a progenitor granule content, size, and sensitivity to stimulants is
cell marker, it is remarkable that little is known about dependent upon growth factors and cytokines present
the function of this antigen. In the literature, CD34 has in its local microenvironment (Gurish and Boyce, 2002;
alternatively been proposed to act as (1) an enhancer Mekori and Metcalfe, 2000).
of proliferation, (2) a blocker of differentiation, (3) a bone The W/Wv mouse possesses two mutations for c-kit
marrow homing receptor, (4) a cell adhesion molecule, and is widely used for the study of mast cell function,
and (5) a blocker of cell adhesion (Baumhueter et al., since these mice virtually lack tissue mast cells (Galli,
1993; Cheng et al., 1996; Delia et al., 1993; Fackler et al., 2000). c-kitW encodes a shortened protein lacking the
transmembrane domain, thereby ablating its expression
on the cell surface (Hayashi et al., 1991; Waskow et*Correspondence: kelly@brc.ubc.ca
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Figure 1. Structure of CD34 and CD43
Schematic structure of full-length murine
CD34 (CD34FL), the naturally occurring trun-
cated form (CD34CT), and CD43 based on pre-
dicted protein sequences. Blue boxes, mucin
domains; green boxes, cysteine-rich domain;
black circles, potential N-linked carbohy-
drates; horizontal bars, potential O-linked
carbohydrates; PKC, CK2, and TK, potential
phosphorylation sites; DTEL, potential PDZ-
domain docking motif.
al., 2004). These mice also harbor the c-kitWv allele, a increased aggregation was reversible by the ectopic
reexpression of CD34 or CD43. To assess the role ofmissense mutation at position 660 in the kinase domain
(threonine to methionine) (Dastych et al., 1998; Nocka these molecules in vivo, we measured the ability of wild-
type and mutant cells to repopulate a mast cell niche,et al., 1990), resulting in weak kinase activity and poor
response to SCF (Waskow et al., 2004). W/Wv mice have using two experimental model systems. These experi-
ments revealed a complete impairment of cd34//a normal number of stem cells but decreased numbers
of progenitor cells and are anemic (Migliaccio et al., cd43/ cells to repopulate peritoneal mast cells. Inter-
estingly, in one of these experimental models, we ob-1999). These mice can be transplanted with wild-type
bone marrow to restore mast cell populations and cure served a similar decreased ability of mutant cells to
reconstitute bone marrow hematopoietic progenitors.their anemia (Williams and Galli, 2000). Since wild-type
progenitor cells respond to SCF better than endogenous Our results show that CD34 and CD43 play a key role
in blocking mast cell adhesion and suggest that theirW/Wv cells, they have an engraftment advantage in colo-
nizing stem cell niches in W/Wv recipients (Migliaccio function on these cells is to enhance their ability to
migrate to new microenvironments.et al., 1999).
To explore the function of CD34 on hematopoietic
cells, we have exploited our observation that this protein Results
but not its closest homologs is expressed by murine
mast cells. We compared bone marrow-derived mast Loss of CD34 Leads to Increased Homotypic
Adhesion of Bone Marrow-Derived Mast Cellscell (BMMC) cultures from wild-type and cd34/ mice
and observed a clear increase in the homotypic adhe- To test the function of CD34 on mast cells and their
precursors, bone marrow from cd34/ mice (Suzuki etsiveness of CD34-deficient mast cells. In an attempt to
exacerbate this phenotype, we generated compound al., 1996) and wild-type mice was cultured in vitro under
conditions that select for the outgrowth and maturationmutant mice lacking CD34 and the distantly related,
sialomucin, CD43 (Figure 1). CD43 is expressed bymost of mast cells. Although loss of CD34 had no effect on
the kinetics of mast cell differentiation, proliferation, orhematopoietic cells, and while it has previously been
shown to play a role in blocking leukocyte adhesion degranulation (Drew et al., 2002) (data not shown), light
microscopic analyses of cultures from wild-type and(Manjunath et al., 1995; Ostberg et al., 1998), its function
has never been examined on mast cells. Our results cd34/ littermates revealed one consistent difference:
CD34-deficient mast cells had an increased propensityshow that mast cells lacking CD34 and/or CD43 show
increased aggregation, with mast cells lacking both si- to aggregate. Wild-type cultures consistently grew as
single-cell suspensions, while mast cells lacking thealomucins showing themost profound aggregation. This
CD34 and CD43 Block Mast Cell Adhesion
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Figure 2. Loss of CD34 Increases Homotypic
Aggregation of BMMC
Bar graphs represent the percentage of cells
involved in aggregates (open bars) and the
average number of cells per aggregate (filled
bars) with standard deviation error bars. Val-
ues are indicated as significantly different
from wild-type or vector alone with (**p 
0.01).
(A) BMMC from littermate and sex-matched
wild-type and cd34/mice. Graphs show de-
gree of aggregation from two independently
derived sets of littermate-matched mast
cells.
(B) cd34/ BMMC expressing the GFP-con-
taining retrovirus pMXpie alone or pMXpie
containing CD34FL or CD34CT. Data show ag-
gregation quantification for two indepen-
dent infections.
CD34 antigen showed small aggregates (8 2 cells per served for cells expressing either CD34FL (2%  5%
aggregation and 2  3 cells per clump) or CD34CTaggregate) with 16%  7% of cells involved in homo-
typic adhesion (Figure 2A). Greater than 1500 cells were (0.1%  0.3% aggregates, with 1  1 cell per clump).
The reexpression of recombinant CD34 by these cellscounted in this and subsequent assays to ensure these
differences were consistent. Similar results were ob- after infection was confirmed by flow cytometry (data
not shown). Our data suggest that CD34 is necessarytained when cells were mechanically dissociated into
single-cell suspensions, plated at the same density, and and sufficient to inhibit mast cell aggregation.
observed after overnight incubation.
To verify that loss of CD34 was responsible for this Loss of the Sialomucin, CD43, Also Leads
to Homotypic Aggregation/Adhesionobserved aggregation, cd34/ bone marrow cells were
infected with a GFP-containing retrovirus alone Our observation that CD34 confers an antiadhesive
function on blood cells is reminiscent of previous reports(pMXpie) or with the same retrovirus expressing either
full-length (CD34FL) or cytoplasmically truncated CD34 showing that CD43, a distantly related sialomucin ex-
pressed on most hematopoietic lineage cells, also is(CD34CT ). The latter form corresponds to a naturally oc-
curring splice variant of CD34 and results in the deletion capable of blocking adhesion (Ardman et al., 1992; Man-
junath et al., 1995; Ostberg et al., 1998; Walker andof the bulk of the cytoplasmic domain via a premature
stop codon (Nakamura et al., 1993) (see Figure 1). Cells Green, 1999). Although CD43 lacks many of the bio-
chemical motifs associated with the CD34 family (Doy-were cultured for at least 6 weeks in media containing
IL-3 and puromycin and sorted by flow cytometry for onnas et al., 2001), it shares a large extracellular mucin
domain (Figure 1). To test whether this molecule playsGFP expression prior to the assessment of GFP-positive
cells for homotypic adhesion by fluorescence micros- a similar role in blocking mast cell aggregation, we es-
tablished mast cell cultures from the bone marrow ofcopy (Figure 2B). For cells infectedwith the vector alone,
19%  7% of cells formed aggregates with 7  2 cells cd43/ and cd34//cd43/ double-deficient mice. Al-
though we found no difference in the ability of CD43-per clump. Strikingly, virtually no clumping was ob-
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deficient mast cells to differentiate (data not shown), agents compared to controls, and aggregates failed to
accumulate during overnight incubation in the presencethese cells were much more prone to aggregation than
either cd34/ or wild-type mast cells (70%  20% ver- of these compounds (Figure 4A). Thus, homotypic adhe-
sion of sialomucin-deficient mast cells is a process thatsus 16%  7% or 3%  2%, respectively; Figure 3A).
In addition, the size of these aggregateswasmuch larger is dependent upon divalent cations and may involve
integrins. A similar effect was also observed for cd34/than those observed in cultures of either cd34/ or wild-
type mast cells (30  15 cells/aggregate versus 8  2 and cd43/ BMMC (data not shown).
In an effort to determinewhich adhesion proteinmedi-and 4  2, respectively). Interestingly, loss of CD34 and
CD43 had an additive effect on homotypic adhesion: ates this aggregation, cd43/ or cd34//cd43/ cells
were disaggregated mechanically and incubated with94%  7% of the cd34//cd43/ mast cells were in
aggregates, and the size of these aggregates was much blocking antibodies to 1-, 2-, 4-integrins, ICAM-1, or
SgIGSF (Ito et al., 2003). None of these antibodies werelarger thanmast cell aggregates formed in cultures lack-
ing either cd43/ or cd34/ (94  50 cells/aggregate able to disrupt reaggregation of these BMMC (data not
shown). This suggests that either another molecule isversus 30  15 and 8  2, respectively; Figure 3A).
Again, we saw no obvious defect in the proliferation or responsible for this aggregation or that several adhesive
receptors are involved, and this effect cannot be over-differentiation capacity of these double-deficient cells.
To test whether the increased aggregation reflects a come by blocking only one of these proteins.
To test whether this antiadhesive activity on wild-general increase in nonspecific cell adhesion, we exam-
ined the ability of wild-type and cd34//cd43/ mast type mast cells was cell autonomous, we labeled either
cd34//cd43/ or cd34/ BMMC with the red fluores-cells to bind to fibronectin in vitro. Cd34//cd43/mast
cells had a higher propensity to bind this extracellular cent dye CSA-SE and mixed them with cd34/ mast
cells infected with GFP and CD34CT. None of the GFP/matrix, without stimulation, than wild-type mast cells (see
Supplemental Figure S1 at http://www.immunity.com/cgi/ CD34-positive cells aggregated with CSA-SE-positive
cd34//cd43/ or cd34/ cells (Figure 4B). From thesecontent/full/22/1/43/DC1/). We conclude that CD34 and
CD43 both play a role in blocking cell aggregation and experiments, we conclude that the negative regulation
of cellular adhesion by CD34 is cell autonomous andthat the loss of both molecules has an additive effect
on cell adhesion. that it is unable to lead to the disaggregation of cells
in trans.To test whether CD34 and CD43 are functionally re-
dundant on mast cells, cd43/ bone marrow was in-
fected with either a control virus vector or with vectors CD34 and/or CD43 Are Required for Optimal Mast
expressing CD34FL or CD34CT (Figure 3B). Ectopic ex- Cell Progenitor Migration In Vivo
pression of CD34FL and CD34CT led to a partial reversal To determine whether the loss of CD34 and CD43 affect
of the aggregation phenotype over controls, with a de- the ability of mast cell precursors to migrate to periph-
crease from 76%  6% aggregation and 31  10 cells eral tissues, we quantified the number of mature mast
per aggregate (vector-alone cells) to 41%  19% for cells within different tissues of wild-type, cd34/,
CD34FL (14  5 cells per aggregate) and 27%  2% for cd43/, and cd34//cd43/mice. CTMCwere enumer-
CD34CT (14  6 cells per aggregate). CD43 was also ated using toluidine blue and Giemsa stains in the skin
introduced into cells using pMXpie and showed com- of the ear and back and in the peritoneal cavity, respec-
plete reversion of aggregation (data not shown). tively. MMCwere quantified as Alcian blue-positive cells
Overexpression of CD34FL in cd34//cd43/ mast in the mucosa of the intestine. Surprisingly, we found a
cells also led to a decrease in aggregation from 98%  similar number of connective tissue and mucosal mast
1% and 45  11 cells per aggregate (vector control) to cells in each tissue examined, regardless of their cd34
74%  17% and 31  16 cells per aggregate (Figure or cd43 genotype (Figure 5A). Thus, our data suggest
3C). CD34CT decreased adhesion to 6%  4% aggrega- that, despite the profound differences in mast cell adhe-
tion (4 2 cells per aggregate; Figure 3C). Ectopic CD43 sion observed in vitro, CD34- and/or CD43-deficient
expression led to complete disaggregation of cd34// mast cell progenitors migrate to tissues during develop-
cd43/ mast cells to 2.3%  0.9% (Figure 3C). In sum- ment in sufficient numbers to result in the appropriate
mary, our data suggest that, on mast cells, CD34 and frequency of mature tissue mast cells in adult mice. We
CD43 have overlapping functions in blocking adhesion also assessed the frequency of mast cell progenitors
and that the loss of either or both of these molecules (MCp) per 106 mononuclear cells (MNC) in adult mice
can be reversed by the ectopic reexpression of CD34 under normal conditions, using a limiteddilution analysis
or CD43. (Crapper and Schrader, 1983; Gurish et al., 2001). There
was no significant difference observed for the bonemar-
row or spleen between wild-type, cd34/, cd34/, andHomotypic Adhesion Is Divalent Cation Dependent
and Cell Autonomous cd34//cd43/ mice (Figure 5B).
In order to evaluate the kinetics of mast cell precursorCellular adhesion mediated by integrins is dependent
upon the presence of divalent cations (Leitinger et al., migration into adult tissues, we used intraperitoneal in-
jection of distilled water to ablate the local CTMC and2000). In an effort to determine whether the enhanced
aggregation of mucin-deficient mast cells is cation de- then monitored the mast cell repopulation of this com-
partment over time. This technique has been previouslypendent, mast cells were cultured in media supple-
mented with 1 mM EDTA and/or 1 mM EGTA in vitro. shown to eradicate peritoneal mast cells (about 2% of
the resident peritoneal hematopoietic cell population)After 10 min in culture, cd34//cd43/ cells showed no
aggregation in the presence of either or both chelating and stimulate the influx of mast cell progenitors from
CD34 and CD43 Block Mast Cell Adhesion
47
Figure 3. CD34 and CD43 Both Block BMMC Aggregation
Bar graphs represent the percentage of cells involved in aggregates (open bars) and the average number of cells per aggregate (solid bars)
with standard deviation error bars. Values are indicated as significantly different from wild-type or vector alone (*p  0.05 or **p  0.01).
(A) Aggregation of cd43/ and cd34//cd43/ BMMC. Mast cells were independently derived from two mice of each genotype.
(B) Aggregation of cd43/ BMMC expressing the GFP-containing retrovirus pMXpie alone with pMXpie containing CD34FL or CD34CT. Data
show results from two independent infections.
(C) Aggregation of cd34//cd43/ BMMC expressing pMXpie alone or pMXpie containing CD34FL, CD34CT, or CD43.
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Figure 4. Homotypic Adhesion Is Divalent
Cation Dependent and Cell Autonomous
(A) Cellular aggregation is completely lost
upon addition of 1 mM EDTA and/or EGTA.
Micrographs show double-deficient cd34//
cd43/ BMMC in the absence and presence
of these chelators.
(B)Cd34//cd43/ cells or cd34/ cells were
labeled with CSA-SE and were mixed with
GFP-positive CD34CT expressing BMMC. Cells
were allowed to aggregate overnight and
were observed under fluorescence micros-
copy to assess degree of mixed aggregation.
the bone marrow without drastically altering the total in vivo. W/Wv mice were sublethally irradiated and in-
jected with wild-type bone marrow cells mixed withnumber of peritoneal cells (Kanakura et al., 1988). Dis-
equal numbers of either cd34/, cd43/, or cd34//tilled water was injected into the peritoneum of wild-
cd43/ bonemarrow cells in a competitive repopulationtype, cd34/, cd43/, and cd34//cd43/ mice, and
assay. As a control, W/Wv mice were also injected withthe frequency of resident mast cells in peritoneal lavage
cd34//cd43/ bone marrow cells alone (Figure 6A). Towas assessed at 2, 6, 12, 16, and 21weeks after injection
distinguish between the two donor populations, some(Figure 5C). Wild-type mice showed an immediate abla-
mice were injected with CD45.1 wild-type cells andtion of mast cells after water injection and required 21
mutant cells (CD45.2). CD45.1 is a variant of CD45, aweeks to recover a near-normal frequency of mast cells.
pan-hematopoietic marker, and is commonly used forCd34//cd43/ mice showed a near complete absence
distinguishing between donor populations in stem cellof mast cell recovery even after 21 weeks (p  0.002).
transplantation experiments (Hasumura et al., 2003).Although the recovery of mast cells in cd34/ or cd43/
Eleven to twelve weeks after injection, the frequencysingle-deficientmice fell betweenwild-type andcd34//
of peritonealmast cellswas evaluated by flowcytometrycd43/ levels, it was not low enough to be considered
based on their distinctive high side-scatter propertiesstatistically different from wild-type mice (p  0.61 and
(as a measure of cell granularity) and their high expres-0.06, respectively; Figure 5C). We conclude that al-
sion of c-kit (Figure 6B). C-kithi peritoneal cells fromthough cd34//cd43/ mice show no dramatic de-
nonreconstitutedwild-typemicewere positive for Fc	RI,crease in the frequency of mast cells in adult tissues at
confirming their identity as mast cells (data not shown).steady state, after mast cell ablation they display a clear
Wild-type, cd34//cd43/, and W/Wv mice were useddefect in the kinetics of mast cell progenitor migration
as controls. As expected, high side-scatter, c-kithi perito-into the peritoneum, consistent with a requirement for
neal cells were virtually undetectable in nonreconstitu-these molecules for efficient homing in vivo.
ted W/Wv mice (Figure 6B). Interestingly, mice reconsti-
tuted with cd34//cd43/ bone marrow alone did not
CD34 and/or CD43 Are Required for Mast Cell show significant peritoneal mast cell reconstitution (Fig-
Repopulation of the Peritoneal Cavity in W/Wv Mice ure 6B), suggesting a potent defect in their ability to
W/Wv mice, which bear mutations in c-kit, virtually lack populate vacant mast cell niches in the peritoneum. In
tissue mast cells and have been widely used as a model contrast, significant numbers of mast cells were found
system for testing the ability of mutant mast cells to in W/Wv mice that had been competitively reconstituted
repopulate adult tissues (Galli, 2000). Here, we used with wild-type and cd34/, cd43/, or cd34//cd43/
these mice as a permissive system for measuring the bone marrow (Figure 6B).
ability for mutant bone marrow precursors to compete To determine the frequency of wild-type and mutant
mast cells in the peritoneal cavity after competitive re-withwild-type cells for reconstitution of amast cell niche
CD34 and CD43 Block Mast Cell Adhesion
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Figure 5. CD34 and CD43 Are Essential for Optimal Recovery of Peritoneal Mast Cells
(A) Mast cell numbers in vivo are similar in wild-type and cd34/, cd43/ , and cd34//cd43/ mice. Ear and back skin was sectioned and
stained with toluidine blue. The number of purple, granular-positive mast cells per field is shown. Peritoneal lavage cells were cytocentrifuged
and Giemsa stained to identify mast cells. For mucosal mast cells, intestines were sectioned and stained with Alcian blue and safranin. Alcian-
blue-positive mast cells were quantified per villus for each mouse. Error bars show standard deviation values.
(B) The frequency of mast cell progenitors per 106 mononuclear cells is similar in wild-type, cd34/, cd43/, and cd34//cd43/ bone marrow
and spleen. Cells from each tissue were plated in a limited dilution analysis with IL-3 and analyzed after 14 days for mast cell colony growth.
The frequency of MCp in bone marrow and spleen was measured in three independent experiments. Error bars show standard deviation values.
(C) Number of peritoneal mast cells from wild-type cd34/, cd43/, and cd34//cd43/ mice at various time points after ablation of mast
cells by intraperitoneal injection of water. Each symbol represents one mouse. Average for each genotype is shown as a horizontal line. Blue
diamonds, wild-type; green squares, cd34/; orange circles, cd43/; and red triangles, cd34//cd43/. Values are indicated as significantly
different from wild-type (**p  0.01).
constitution of W/Wv mice, these cells were tested for had been solely reconstituted with CD43 or CD34
cells. (The higher level of CD34 expression in reconstitu-the presence or absence of CD34 and CD43 on their
surface. As controls for CD34 and CD43 expression, ted mice may reflect upregulation of this protein after
transplantation. [Figure 6C]). Accordingly, for mice com-nonreconstituted wild-type and cd34//cd43/ mice
were analyzed in a parallel experiment (Figure 6C). Virtu- petitively reconstituted with wild-type CD45.1 and
cd34//cd43/ bone marrow, 90% of the resultingally all mast cells resulting from competitive recon-
stitution by wild-type and cd34//cd43/ cells were of peritoneal mast cells were CD45.1 (data not shown).
Mice reconstitutedwithwild-typeand cd43/bonemar-wild-type origin (CD43CD34). These cells repopulated
peritoneal mast cells to similar frequencies as mice that row cells did not display a significant advantage for wild-
Immunity
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type cells to reconstitute the peritoneal mast cell niches, populated with only cd34//cd43/ bone marrow cells
(no wild-type competitors) did not have any detectableshowing a similar frequency of CD43mast cells to that
predicted for an equal contribution by wild-type and c-kit-positive cells in the bone marrow (Figure 7A). This
suggests that CD34 and/or CD43 are essential for stemcd43/ cells (Figure 6C). Competitive reconstitution by
wild-type and cd34/ cells showed the same number cell engraftment in this W/Wv model.
To determine the donor origin of c-kit-positive cellsof CD34 mast cells as reconstitution by CD34 cells
alone; however, this was not significantly different to in competitively reconstituted mice, these cells were
analyzed for CD43 and/or CD45.1 expression. For micethe predicted equal contribution (Figure 6C). Our results
suggest that, under competitive and noncompetitive reconstituted with wild-type CD45.1 and cd34/
CD45.1 cells, we found that virtually all c-kit cells wereconditions, cd34//cd43/ cells are severely defective
in their ability to reconstitute peritoneal mast cells. CD45.1, suggesting that cd34/ cells were unable to
engraft the bone marrow (Figure 7B). In contrast, mice
reconstituted with wild-type CD45.1 and cd43/CD34 Is Required for Progenitor Cell Repopulation
CD45.1 cells showed equal contribution from eachof the Bone Marrow in W/Wv Mice
population, implying that there was no disadvantage forOur observation that loss of CD34 and CD43 prevents
cd43/ cells (Figure 7B). In mice competitively reconsti-mast cell reconstitution of the peritoneal cavity of W/Wv
tuted with wild-type and cd34//cd43/ cells, virtuallymice does not necessitate a mast cell precursor defect
all c-kit-positive cells expressed CD45.1 and/or CD43,per se, but could also be explained by a stem cell defect
indicating wild-type origins (Figure 7B). Therefore, inof mutant cells within the bone marrow. This idea was
this model, CD34 itself is essential for hematopoieticnot supported by our observation that there was no
progenitor engraftment.competitive advantage for wild-type or mutant bone
marrow cells to contribute to multilineage reconstitution
Discussionin lethally irradiated wild-type mice (data not shown).
However, since mice with mutations in c-kit have been
Despite the widespread use of CD34 as a selectiveshown to be particularly sensitive to engraftment after
marker of hematopoietic precursor cells over the lastsublethal irradiation (Benveniste et al., 2003; Vecchini
two decades, its function on hematopoietic cells haset al., 1993), we examined the frequency ofwild-type and
remained elusive. Here, we have taken advantage of ourmutant hematopoietic progenitors in the bonemarrowof
observation that CD34 is a marker of murine mast cellscompetitively reconstituted W/Wv recipients.
to address the hematopoietic function of this antigen.Since c-kit expression was not detected on bonemar-
Our results provide compelling evidence that CD34 asrow (or spleen) cells from W/Wv mice (either due to
well as the distantly related sialomucin, CD43, are nega-decreased number of progenitors (Migliaccio et al.,
tive regulators of mast cell/mast cell progenitor adhe-1999) and/or decreased level of expression (Hayashi et
sion in vitro and in vivo.al., 1991; Waskow et al., 2004) (Figure 7 and data not
shown), all c-kit-positive bone marrow cells in reconsti-
tuted mice were donor derived. We could therefore enu- CD34 as Blocker of Differentiation, Enhancer
of Proliferation, or Homing Receptor?merate the frequency of wild-type and mutant hemato-
poietic progenitors simply by quantifying the frequency The speculation in the literature that CD34, when ex-
pressed by hematopoietic cells, can act as a blocker ofof c-kitCD45.1/CD43 and c-kitCD45.1/CD43 cells,
respectively. differentiation or enhancer of proliferation stems from
three observations. First, CD34 is normally expressedIn wild-type and cd34//cd43/ mice, approximately
20% of bone marrow cells express c-kit (Figure 7A). at the highest levels by rapidly proliferating multipotent
hematopoietic progenitors and is progressively lost asAlthough there was no expression of c-kit on bone mar-
row cells from nonreconstituted W/Wv, upon competi- these mature (reviewed in Krause et al., 1996). Thus, its
expression pattern correlates with a potential role intive transplantation with wild-type and cd34/, cd43/,
or cd34//cd43/ bone marrow cells, c-kit-positive these processes. Second, one strain of cd34 knockout
mice was found to have a decreased number of progeni-cells were detected at the same frequency as wild-type
bone marrow (Figure 7A). Interestingly, W/Wv mice re- tor cells in embryonic and adult tissues, and adult-
Figure 6. CD34 and CD43 Are Required for Optimal Peritoneal Mast Cell Reconstitution of Mast Cell-Deficient Mice
(A) Schematic showing experimental design of competitive reconstitution of W/Wv mice. Sublethally irradiated mice were intravenously injected
with a 1:1 mixture of wild-type and either cd34/, cd43/, or cd34//cd43/ bone marrow cells, or cd34//cd43/ alone. Eleven to twelve
weeks later, mast cell reconstitution was assessed.
(B) Percentage of peritoneal mast cells was evaluated for nonreconstituted wild-type, cd34//cd43/, and W/Wv mice for competitively
reconstituted W/Wv mice (with wild-type and either cd34/, cd43/, or cd34//cd43/ bone marrow) and noncompetitively reconstituted
cd34//cd43/ bone marrow. Mast cells were identified as c-kithi SSChi cells. Error bars show standard deviations. Value is indicated as
significantly different from the average percentage of c-kit-positive cells resulting from competitive reconstitution (**p  0.01).
(C) Flow cytometric analysis of c-kithi SSChi peritoneal cells from nonreconstituted wild-type and cd34//cd43/mice (as controls) and
competitively reconstituted W/Wv mice that were injected with a 1:1 mixture of wild-type and either cd34/, cd43/, or cd34//cd43/ bone
marrow. The bar graphs show the relative reconstitution of CD43 and CD34 mast cells for mice reconstituted with CD43 and CD34 bone
marrow alone and mice competitively reconstituted with wild-type and knockout cells. Also shown is the predicted frequency of CD43 and
CD34 cells assuming equal contribution of wild-type and cd34//cd43/ cells (gray bars). Error bars show standard deviations. Values are
indicated as significantly different from the predicted values for equal reconstitution (**p  0.01).
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Figure 7. Loss of CD34 Prevents Bone Marrow Engraftment
(A) Graphical representation of the percentage of c-kit-positive bone marrow cells, assessed using flow cytometry, in the bone marrow of
nonreconstituted wild-type, cd34//cd43/, and W/Wv mice. Also shown is the number of c-kit-positive cells that resulted from competitive
reconstitution of W/Wv mice by wild-type and either cd34/, cd43/, or cd34//cd43/ bone marrow or noncompetitive reconstitution with
cd34//cd43/ bone marrow alone. Error bars show standard deviations. Values are indicated as significantly different from the predicted
values for equal reconstitution (**p  0.01).
(B) C-kit-positive cells were gated for competitively reconstituted W/Wv mice and analyzed for expression of CD45.1 (wild-type) and/or CD43
to determine which donor these cells were derived from. Error bars show standard deviations. Values are indicated as significantly different
from the predicted values for equal reconstitution (**p  0.01).
(C) Proposed model for the function of CD34 and CD43 in vitro and in vivo. Loss of CD34 or CD43 results in increased adhesion of mast cells
in vitro, with the loss of both these molecules increasing this adhesion, which can be reversed by ectopic expression of CD34 or CD43. The
lack of CD34 in vivo causes decreased bone marrow engraftment, and the loss of CD34 and CD43 impairs the recovery of peritoneal mast
cells from endogenous bone marrow-derived precursors.
derived progenitor cells were somewhat defective in adhesion, we propose that the previous reports of an
effect on proliferation and differentiation could reflecttheir ability to proliferate in vitro (Cheng et al., 1996).
Finally, ectopic expression of CD34 in amyelomonocytic downstream effects due to inappropriate cell adhesion.
More recently, it has been argued that CD34 may actcell line that is inducible for macrophage differentiation
(M1) was shown to block terminal differentiation into as a specific bone marrow homing receptor. This is
based on the fact that, in short-term homing assays,macrophages and to maintain cells in a highly prolifera-
tive “immature” state (although it was incapable of cd34/ hematopoietic progenitors migrate poorly to the
bone marrow and tend to be recovered more frequentlyblocking the differentiation of two other differentiation-
inducible cell lines [Fackler et al., 1995]). Although these from the spleen than their wild-type counterparts
(Krause et al., 2001). However, the inability of cd34/experiments are indirect, they are consistent with a role
for CD34 in maintaining hematopoietic progenitors in an hematopoietic cells to home to the bone marrow in
short-term assays (Krause et al., 2001) may, in fact,undifferentiated state or in enhancing their proliferation
prior to terminal differentiation. Our observation that reflect increased adhesion of these cells in peripheral
tissues (spleen) rather than the loss of a specific homingcd34/ and wild-type mast cells mature and differenti-
ate at identical rates would argue strongly against a receptor. Our observation that terminally differentiated
mast cells express high levels of CD34 (Drew et al.,significant, global role for CD34 in these processes
(Drew et al., 2002) (although a selective role in some 2002) would argue strongly against a global role for this
molecule as a specific, bone marrow homing receptor.lineages is still a formal possibility). Based on our obser-
vation that cells lacking CD34 tend to exhibit enhanced In mice, mast cell precursors leave the bone marrow as
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undifferentiated progenitors prior to terminal differentia- Function of CD34 and CD43 on Mast Cells
tion intomaturemast cells in theperipheral tissues (Galli, and Their Progenitors
2000). Sincematuremast cells are virtually undetectable The mechanistic details of mast cell progenitor migra-
in adult mouse bone marrow, the data do not support tion remain to be clarified. However, there has been a
a role for CD34 in bone marrow homing of mast cells. recent demonstration that these cells require 47 integ-
However, our observation that the absence of CD34 rin to home to the intestine and Mac-1 to home to the
on hematopoietic progenitors prevents bone marrow peritoneum (Gurish et al., 2001; Rosenkranz et al., 1998).
engraftment (Figures 7A and 7B) supports the possibility Our results suggest that it is not only the presence of
that CD34 is important for bone marrow homing when adhesion molecules that is important for the proper lo-
it is expressed on progenitor cells. calization of mast cell progenitors to tissues, but also
the presence of antiadhesion molecules that prevent
CD34 as a Proadhesion or an Antiadhesion Molecule? inappropriate adhesion during migration and/or permit
Although there was initially speculation that CD34 could the initial release of mast cell precursors from the
act as an antiadhesion molecule, based on its similar bone marrow.
structure to other antiadhesion molecules, reciprocal Since mutant mice have normal numbers of tissue
expression with adhesion molecules, and ultrastructural mast cells at steady state (Figure 5A), our data may
localization on endothelial cells (Delia et al., 1993), this suggest thatmutantmast cell precursors have the ability
hypothesis quickly lost favor with the discovery that, on to seed peripheral tissues during embryogenesis and
high endothelial venules (HEV), CD34 acts as a proadhe- that these precursors persist in the tissues to adulthood
sive ligand for L-selectin (Baumhueter et al., 1993). Ele- without a requirement for recolonization unless they are
gant experiments have shown that, when expressed by depleted. The ability of these precursors to seed periph-
HEV, CD34 and its close relative, Podocalyxin, undergo eral tissues early in development could therefore reflect
specific posttranslational modifications that endow several factors, including phenotypic difference be-
them with the ability to bind to L-selectin expressed on tween fetal and adult mast cell precursors (Rodewald
the surface of migrating lymphocytes (Baumhueter et et al., 1996) or differences in the mechanisms that allow
al., 1993; Bistrup et al., 1999; Sassetti et al., 1998). This colonization early in life.
leads to lymphocyte tethering to this specialized endo- It has been previously shown using chimeric mice
thelium, followed by integrin-dependent firm adhesion that, in the adult, mast cell progenitors originate in the
and extravasation into lymph nodes (Hickey et al., 2000). bone marrow, migrate to the peritoneum, and subse-
Based on these data, it has been proposed that CD34 quently differentiate (Kanakura et al., 1988). Our results
may serve a similar function in tethering hematopoietic show a lack of peritoneal mast cell recovery in cd34//
cells to the bone marrow microenvironment. An impor- cd43/ mice, despite normal frequencies of bone mar-
tant caveat to this hypothesis is that L-selectin binding row MCp (Figures 5B and 5C), and suggest that there
to CD34 and Podocalyxin is critically dependent upon is a defect in the migration of mast cell precursors to
the appropriateHEV-specific glycosylation of these anti- peripheral tissues in response to challenge. Further-
gens. Since these posttranslational modifications are more, we have found that in vitro mutant mast cells
exquisitely tissue specific and undetectable on CD34 or show no difference in the kinetics of maturation or viabil-
Podocalyxin expressed by the vast majority of vascular ity (Drew et al., 2002 and data not shown), excluding
endothelial cells or by hematopoietic cells, it is likely the possibility that this observation is due to a defect
that CD34’s proadhesive role on HEV is an important in survival or differentiation. Together, our results sup-
exception rather than the rule. port the hypothesis that the impairment in peritoneal
Nevertheless, in apparent support of this “proadhe- repopulation is due to retention of mutant precursors
sion hypothesis,” several studies have shown that anti- within the bone marrow or inappropriate adhesion to
bodies to human CD34 (and CD43) induce antigen
the vasculature, thereby preventing these cells from
capping and homotypic aggregation of CD34/CD43-
reaching the peritoneal cavity.
expressing progenitor cells (Majdic et al., 1994; Tada et
al., 1999). Although these results can be interpreted to
The Role of CD34 and CD43 in Hematopoieticsuggest an activation-dependent adhesive function for
Progenitor Cell Colonization of Bone MarrowCD34, we propose an equally plausible alternative hy-
Intriguingly, we also found that, in a competitive bonepothesis: capping of CD34/CD43 with bivalent antibod-
marrow reconstitution assay of W/Wvmice, the resultingies leads to the “unmasking” of adhesion molecules,
peritoneal mast cells were derived predominantly fromand this results in cell aggregation. It is noteworthy that
wild-type donors (Figures 7A and 7B). This observationin these antibody crosslinking studies, homotypic ag-
could be due to a functional lesion at a variety of stagesgregation required 2-integrin activation and divalent
in mast cell development, including (1) a bone marrowcations (Majdic et al., 1994). Thus, it is likely that the
progenitor cell defect, (2) a mast cell lineage survivallocal clearing of CD34 and CD43 in the plasma mem-
defect, or (3) a migratory defect of the mast cell progeni-brane leads to enhanced integrin function due to the
tors. Our data, showing that under competitive and non-unmasking of these molecules rather than proadhesive
competitive conditions cd34//cd43/ bone marrowfunction conferred directly by CD34 and CD43. We have
cells fail to reconstitute c-kit-positive cells in the boneyet to clarify whether these molecules are responsible
marrow of W/Wv mice (Figure 7A), fit most closely withfor the homotypic aggregation in cd34//cd43/
the first hypothesis. Although we have not previouslyBMMC, but our observation that aggregation is divalent
observed a significant defect in the ability ofmutant cellscation dependent is consistent with this hypothesis (Lei-
tinger et al., 2000). to competitively reconstitute lethally irradiatedwild-type
Immunity
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mice, the available niches in sublethally irradiated W/Wv blockers of cell-cell interactions and prevent inappropri-
mice are more limiting and therefore would cause tight ate adhesion by blocking the binding of adhesive mole-
competition between the two donor populations. Our cules to adjacent cells via their bulky, highly negatively
results suggest that wild-type cells seed the bone mar- charged extracellular domains. On hematopoietic pro-
row more efficiently in the latter, more sensitive system. genitors, these proteins may provide a means of releas-
Interestingly, we found CD34 to be more important ing cells from one niche and allowing them to migrate
than CD43 for bone marrow repopulation in this W/Wv to new microenvironmental niches for maturation or, in
model (Figure 7B). While this explains the defect in mu- the most extreme cases (during embryogenesis or dur-
tant mast cell colonization of the peritoneum in this ing mobilization of stem cells with G-CSF), endow these
model, it also points to an important role of CD34 in cells with the ability to enter the peripheral blood and
hematopoietic progenitor cell engraftment of the bone seed new tissues. Our results support the original, and
marrow and is consistent with a previous report showing largely abandoned, hypothesis that CD34 inhibits cellu-
impaired short-term homing of cd34/ progenitors to lar adhesion (Delia et al., 1993) and show a clear function
the bone marrow (Krause et al., 2001). It also closely for CD34 on hematopoietic cells both in vitro and in vivo.
correlates with the observed upregulation of CD34 in
Experimental Proceduresbone marrow reconstitution experiments (Sato et al.,
1999). The decreased ability for cd34/ cells to engraft
Micecould be due to (1) increased inappropriate adhesion or
All mice were maintained under pathogen-free conditions at the(2) the requirement for CD34 binding an unknown ligand
Biomedical ResearchCentre transgenicmouse unit, andprocedures
within the bone marrow environment. However, since involving mice were approved by the University of British Columbia
the loss of CD34 does not affect the ability of progenitor Animal Care Committee. C57Bl/6 and CD45.1 (Bl/6SJL) mice were
cells to bind P-/E-/or L-selectin (data not shown), this used as wild-type mice. Cd34/ mice (on a C57Bl/6 background)
were kindly provided by Dr. T.W. Mak (Suzuki et al., 1996), andexcludes these selectins as potential ligands for CD34
cd43/ mice (also on a C57Bl/6 background) were kindly providedin this context. In light of our in vitro observations show-
by Dr. Blair Ardman (Carlow et al., 2001; Manjunath et al., 1995).ing that CD34 and CD43 block mast cell adhesion and
Cd43/micewere identified byCD43 cell-surface staining of periph-
are required for optimalmast cell recovery after ablation, eral blood cells using anti-CD43mAb S7 and flow cytometry (Carlow
we propose a block in nonspecific adhesion to be the et al., 2001). Cd34//cd43/ double-deficient mice were generated
most likely mechanism for impaired bone marrow en- by first crossing cd34/ and cd43/ single-deficient mice to pro-
duce cd34//cd43/ F1 heterozygotes and subsequently crossinggraftment of mutant cells.
siblings to generate double-homozygous double-null mice. FemaleIn summary, our results show that CD34 and CD43
WBB6F1/J-kitW/kitW-v(W/Wv) mice were purchased from The Jack-are important in preventing adhesion of mast cells
son Laboratory.in vitro and are important in themigration of their precur-
sors to the peritoneum (Figure 7C). In addition, our re- Bone Marrow-Derived Mast Cells
sults provide evidence for the importance of CD34 on Bone marrow was flushed from the femurs of homozygous mutant
bone marrow stem cells, suggesting that, under condi- or wild-type mice. Red blood cells were lysed using 0.1 M NH4Cl,
and the remaining cellswerewashed and resuspended inRPMI 1640tions of a limited number of niches, these mutant cells
with penicillin/streptomycin, sodium pyruvate, glutamine (RPMI),are at a disadvantage to their wild-type counterparts
10% fetal bovine serum, and 16 U/ml IL-3 obtained from WEHI-3B(Figure 7C).We propose that CD34 and its homologs can
conditioned media (Tsuji et al., 1991). Cells were transferred to newact as both proadhesive and antiadhesive molecules,
flasks periodically during culture to remove adherent cells, and they
depending on the context of their expression and post- were grown for aminimumof 4weeks to allow formast cell differenti-
translational modifications (Doyonnas et al., 2001; Niel- ation (Tsuji et al., 1991).
sen et al., 2002). In the specialized case of HEV, we
propose that CD34 family members may have a dual Nucleic Acid Analyses
Genotypic analysis of wild-type and cd34/ littermates was per-function. As has been shown previously, these mole-
formed using ear punches digested with proteinase K in lysis buffercules may first act as proadhesives to tether lympho-
(50 mM Tris [pH 8.0], 2 mM NaCl, 10 mM EDTA 1% SDS with 1mg/cytes to HEV via L-selectin recognition of HEV-specific
ml proteinase K) at 55
C for 40 min. Tissue samples were thenglycosylations decorating CD34-type proteins (Baum- diluted with water, heated for 10 min at 100
C, then further diluted
hueter et al., 1993; Sassetti et al., 1998). Subsequently, prior to use as a template for polymerase chain reactions (PCR).
these molecules may be induced to move to the junc- PCR was performed using the following primers (kindly provided
tions between vascular endothelial cells, where they by Dr. Ste´phane Corbel, Biomedical Research Centre, Vancouver,
Canada): forward 5-CCATCTTGGGCACCACTGGTTATT-3 and re-may act as antiadhesives and aid in the disruption of
verse 5-TCTTCCCAACAGCCATCAAGGTTC-3 for the wild-typecell-cell interactions, thereby enhancing lymphocyte ex-
cd34 allele, and forward 5-AGAACCTGCGTGCAATCCATC-3 andtravasation. In support of this model, it has recently
reverse 5-CACTGTCCTGTCTAGGTTGAACC-3 for analysis of the
been shown that overexpression of one CD34 homolog, neomycin cassette used for homologous recombination of the tar-
Podocalyxin, in adherent monolayers leads to the dis- geted locus (Suzuki et al., 1996). PCR was performed for 40 cycles
ruption of adherens junctions (Takeda et al., 2000). Con- of 94
C for 45 s, 58
C for 55 s, and 72
C for 2 min. Products were
versely, we have shown that deletion of this family mem- resolved on a 2% agarose gel and were visualized using ethidium
bromide. Wild-type mice were identified by a 600 bp CD34 bandber in mice leads to perinatal lethality due to enhanced
but no neomycin band, and cd34/ mice were identified with noadherens and tight junction formation between kidney
wild-type CD34 band and a 1 kb neomycin-CD34 band.glomerular epithelial cells and excessive adhesion be-
To generate full-length mouse CD34 expression constructs
tweenmesothelial layers during embryogenesis (Doyon- (CD34FL), CD34 cDNA (the kind gift of Dr. Mel Greaves, Chester
nas et al., 2001). Beatty Laboratories, London, UK) was excised frompBluescript with
We propose that on mature hematopoietic cells and NotI and XhoI and inserted into pMXpie (a kind gift of Dr. Alice Mui,
Jack Bell Research Centre, Vancouver, Canada). The viral LTRs ofmost vascular endothelia, CD34 and/or CD43 act as
CD34 and CD43 Block Mast Cell Adhesion
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this vector drive expression of CD34 and EGFP (enhanced green was quantified. Isotype-matched hamster IgG2 (Pharmingen), rat
IgG2b, and rat IgG1 (Cedarlane) were used at the appropriate con-fluorescent protein) via a bicistronic mRNA containing an IRES ele-
ment. To generate cytoplasmically truncated CD34 (CD34CT) corre- centrations for controls.
sponding to the naturally occurring CD34 splice variant (Nakamura
et al., 1993), PCR was performed using the following primers: for- Fibronectin Adhesion Assay
ward 5-ACGACTCACTATAGGGCGAAT-3 and reverse 5-TGCT 24-well plates (Nunc) were coated overnight with 50 g/ml fibronec-
CTAGAATTCAAGGTTCCAGCTCCAGCCTTTCTCCTGTAG-3, using tin (Sigma) at 37
C. The next day, wells were washed with PBS, cells
the full-length CD34 cDNA in pBluescript as a template. Sequencing were washed with RPMI (no FBS), and cells were plated in triplicate
confirmed correct amplification of a cDNA with an identical coding in RPMI on the coated plates with no stimulation or with 100 nM
sequence to this splice variant. The resulting band was excised, TPA at 3  105 cells/ml. After 60 min, the number of suspension
digested with XhoI and XbaI, and inserted into pBluescript KS, cells were counted using a hemocytometer, and the percentage of
which was subsequently cut with XhoI and NotI. The gene was adherent cells was calculated.
inserted into the retroviral expression vector, pMXpie. CD43 was
amplified from mouse kidney cDNA using the following primers: Histology
forward 5-GTTAAACCACAAGATGGGCTTGGCAGTTGG-3 and re- To quantify the number of tissue mast cells, sections of ear and
verse 5-GTATGGATGGATGGATGGACGGATTTGGTC-3. A Flag se- dermal skin and the intestine were prepared as follows. Hair was
quence followed by two glycine residues and a ClaI site was added removed from the dermal skin with a depilatory cream, and skin
after the signal peptide, and the fragment was cloned into pMXpie sections were fixed in neutral buffered formalin or 3:1 methanol:gla-
using BamHI and EcoRI. cial acetic acid. Intestinal sections were fixed in 3:1methanol:glacial
acetic acid, sliced longitudinally, andwrapped in a pinwheelmanner.
Tissues were embedded in paraffin, sectioned at 3 m, deparaffin-Retroviral Infections
BOSC cells were transfected overnight using lipofectamine PLUS ized, rehydrated, and stained. Toluidine blue or Giemsa were used
to detect CTMC as described previously (Drew et al., 2002); CTMC(Invitrogen) with pclECO, encoding for retroviral packaging proteins
(Naviaux et al., 1996), and either empty pMXpie-GFP vector or were identified as dark purple granular cells. Intestinal sectionswere
stained with Alcian blue (1% w/v in 0.7 M HCl [pH 0.3]) for 60 minpMXpie-GFP coexpressing CD34FL, CD34CT, or CD43. Bone marrow
was isolated the next day from cd34/, cd43/, or cd34//cd43/ and counterstained with safranin (0.5% w/v in 0.125 M HCl [pH 1.0])
for 30 s as described previously (Madden et al., 1991), and MMCmice and cultured overnight in RPMIwith 15% fetal bovine serum,
8 U/ml IL-3 (from WEHI-3B conditioned media), 10 ng/ml rmIL-6 were identified as small Alcian-blue-positive cells. Sections were
observed under a Zeiss Axioplan2 microscope, and the number of(R&D), and 15% stem cell factor (SCF) conditionedmedia (from baby
hamster kidney cells transfected with mouse SCF, kindly provided mast cells per field of view (CTMC) or per villus (MMC) was deter-
mined. Peritoneal cells were harvested by peritoneal lavage usingby Dr. Ste´phane Corbel, Biomedical Research Centre, Vancouver,
Canada). The next day, BOSC cells were irradiated with 5000 rads, 10 ml FACS buffer (PBS, 10% FBS, 0.05% sodium azide) injected
with a 26 gauge needle and harvested with an 18 gauge needle.and 7  106 bone marrow cells were added with 6 g/ml polybrene
for 2 days. Finally, nonadherent cells were removed and replated Cells were cytocentrifuged, Giemsa stained, and examined using a
Zeiss Axioplan2 microscope.in RPMI with 10% fetal bovine serum, 16 U/ml IL-3 from WEHI-
3B conditioned media to induce mast cell differentiation, and puro-
mycin (0.8 g/ml) was included to select for infected cells. To ensure Mast Cell Precursor Limiting Dilution Analysis
ectopic gene expression, GFP-positive cells were sorted using a To assess the frequency of MCp, a limited dilution analysis was
FACSVantage (Becton-Dickinson) and/or visualized by fluorescence performed as previously described (Crapper and Schrader, 1983;
microscopy (Olympus). Mast cell differentiation was confirmed by Gurish et al., 2001). Briefly, bone marrow was flushed and spleens
homogenous high expression of c-kit detected using flow cytometry were harvested using HBSS 2% FBS from wild-type, cd34/,
(FACSCalibur, Becton-Dickinson) and exhibition of granules de- cd43/, and cd34//cd43/ mice. Spleens were broken up gently
tected by staining cytospun cells with modified Giemsa (Diffquick). between frosted glass slides and filtered. Bone marrow and spleen
cells were then resuspended in 44% Percoll (Amersham) and over-
layed on 67% Percoll, and samples were spun for 20 min at 400 gHomotypic Adhesion Assays
at 4
C. The interface was harvested, washed, and resuspended inHomotypic adhesion was determined by counting the number of
media (RPMI 1640, 10% FBS, glutamine, penicillin/streptomycin,single cells and the number of cells in aggregates within a micro-
sodium pyruvate, nonessential amino acids, 10 mM HEPES, 2-mer-scopic field of view. Percentage aggregation was calculated as the
captoethanol). Cells were counted, serially diluted 2-fold, and 100number of cells in aggregates (number of aggregates times the
l of each dilution (8  102–1  102 cells per well for bone marrowaverage number of cells per aggregate) over the total number of
cells and 8  103–1  103 for splenic cells) was aliquoted into 96-cells counted in each assay. For all aggregation assays, at least
well plates. Each well was supplemented with 105 irradiated wild-1500 cells were counted. For assessment of cation dependence of
type helper spleen cells (3000 rads) and 10 ng/ml rmIL-3 (R&D).cell aggregates, 1 mM EDTA (disodium ethylenediamine tetraace-
Plates were incubated for 14 days and were examined under antate, Fisher) and/or EGTA (ethylenebis(oxyethylenenitrilo)-tetraace-
inverted microscope. MCp colonies were identified as nonadherent,tic acid, Boehringer) was added to BMMC. For cell mixing experi-
medium-sized cells, as previously reported (Crapper and Schrader,ments, cd34/ or cd34//cd43/ BMMC were stained for 7 min at
1983; Gurish et al., 2001), and the number of wells that containedroom temperature with 10 M CSA-SE (SNARF-1 carboxylic acid,
one or more MCp colonies were scored as positive for each plate.acetate, succinimidyl ester, Molecular Probes), washed three times
The number of MNC plated that resulted in 37%of thewells negativein RPMI 10% FBS, and then passed through a 26 gauge needle
for a MCp colony was estimated using the trend function on Micro-ten times to create a single cell suspension. These were then mixed
soft Excel from the plot of the log of the fraction of nonrespondingwith GFP-positive cd34/ mast cells ectopically expressing CD34CT
cultures and the cell number plated.and were incubated overnight to allow the formation of cell aggre-
gates. Cells were examined under an inverted fluorescence micro-
scope (Olympus) using blue and green filters to examine GFP-posi- Mast Cell Recovery
Wild-type and cd34/, cd43/, and cd34//cd43/ mice were in-tive and CSA-SE-stained cells, respectively. Digital photographs of
fluorescent cells were taken with a Sensys1401E camera (Roper jected intraperitoneally with 3 ml sterile distilled water as previously
described (Kanakura et al., 1988). For each genotype and time point,Scientific) using MetaVue (Universal Imaging Corporation) or
RSImage Software. Imageswere formatted and figureswere created three to seven mice were evaluated (the sum of three separate
experiments). At various time points after injection, mice were sacri-using Adobe Photoshop and Adobe Illustrator.
Blocking experiments were performedwith antibodies toward 1-, ficed and theperitoneal lavagewas extracted (see above), cytospun,
and Giemsa stained. Greater than 1500 cells were counted blindly2-, 4-integrins, ICAM-1 (10 g/ml, Pharmingen), and SgIGSF (50
g/ml, kindly provided by Dr. Yukihiko Kitamura). Cells were treated for each animal at each time point using a Zeiss Axioplan2 micro-
scope, and the number of mast cells per mouse was quantified.with blocking antibodies overnight, after which aggregation of cells
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